ONCAlert | 2018 ASCO Annual Meeting
Prostate Cancer Case Studies

Treatment for Newly Diagnosed Prostate Cancer

Targeted Oncology
Published Online:Sep 22, 2017
In this case-based interview, oncologist Nicholas J. Vogelzang, MD, FASCO, FACP; radiologist Rajan, Gupta, MD; and radiation oncologist Glen Gejerman, MD, discuss optimal therapeutic layering and multidisciplinary management of metastatic castration-resistant prostate cancer that progresses through multiple therapies. Practical perspective on the use of bone-targeted therapy to improve outcomes is emphasized.

Optimal Use of Bone-Targeted Therapy for mCRPC


Nicholas J. Vogelzang, MD, FASCO, FACP: This is a 55-year-old who presented with nocturia and a PSA of 4.5. A digital rectal exam revealed a T2 area of hardness. Biopsy was positive for Gleason 3+3, now called combined Gleason scores of 1. Clinical stage was T1c, but he had a lump so maybe it was a d2. Patient went on active surveillance. About a year later, his PSA had risen to 10. Repeat biopsy now showed a Gleason 4+3, and 8 of the 12 cores were positive. So, the patient clearly had more advanced disease. Whether it was there before or not, it is hard to be sure.

He was asymptomatic and started on goserelin. About 6 months or so later, his PSA did not go down. What was unusual is his PSA, in fact, rose to be 34. So, you have a case almost of de novo resistance to hormone therapy. That should only occur in about 5% or less of patients.

CT scan was negative. Because the PSA was rising, they began him on abiraterone and prednisone. Within a short period of time, although his PSA declined to 15, he had a cardiac arrhythmia, which does occur with abiraterone. So, the treating physician decided to switch to enzalutamide. Again, a perfectly appropriate decision. Enzalutamide did not have any negative effects, but also did not lower the PSA much.

So, now another 3 to 4 months goes by and the patient begins to develop back pain—or not even back pain, just an achiness—and some mild fatigue. The doctor says, “Well, let’s reimage.” CT scan shows bone metastases. A fluoride PET bone scan confirms lumbar and pelvic bony metastatic disease. PSA is up to 45, and the ALK phosphatase is starting to rise. The patient has symptoms, mostly fatigue, but also a rising PSA, new findings on x-rays, and new findings on the fluoride PET scan.

At that point, it’s extremely appropriate to begin radium-223. The patient develops a drop in the PSA, which isn’t that common with radium. Normally, the PSA does not drop much, but it fell from 45 to 25. His ALK phosphatase comes down into the normal range, and his symptoms of fatigue begin to improve. He has had 4 doses. The questions are: was this the right sequencing? Should he get additional radium, etc? So, we’re going to cover some of those topics.

Transcript edited for clarity.

November 2014

  • A 55-year old gentleman presented with nocturia and PSA level of 4.5 ng/mL
  • PMH: Insignificant 
  • DRE revealed an abnormal area of hardness
  • Biopsy showed adenocarcinoma of the prostate gland with a Gleason score 6 [3+3], clinical tumor stage T1c                                                                                                                                                                  
  • The patient remained on active surveillance

November 2015

  • When he returned after 1 year:
    • PSA, 10 ng/mL
    • Repeat biopsy showed Gleason 7 [4+3] with 8 of 12 cores positive
    • CT scan was negative for metastases
    • He remained asymptomatic
  • He was started on a 3-month depot injection of goserelin

February 2016

  • PSA, 34 ng/mL
  • CT scan was negative for metastases
  • He was started on abiraterone and prednisone
    • PSA declined to 15 ng/mL and remained stable
    • After 4 months, he developed cardiac arrhythmia attributed to prednisone; he was switched to enzalutamide
    • PSA remained stable

August 2016

  • 3 months following therapy switch, the patient complained of severe fatigue
    • CT scan showed enlarged lumbar spine and pelvic bone metastases
    • 18F-FDG PET showed increased FDG uptake in several areas of the lumbar spine and pelvis
    • PSA, 45 ng/mL
    • ALP, 225 U/I
  • Radium-223 therapy was initiated and enzalutamide was continued
  • After 4 cycles of radium-223:
    • Fatigue decreased significantly
    • PSA, 25 ng/mL
    • ALP, WNL
    • CT showed no new bone metastases
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.